EOMES and myeloid sarcoma: This BCL6–HHEX epistatic interaction does not exhaust other possible epistatic effects, i.e., HHEX knockdown considerably enhanced the expression level of eomesodermin (EOMES), another MS-risk factor identified by GWAS [3].